PERITONEAL CANCER
Clinical trials for PERITONEAL CANCER explained in plain language.
Never miss a new study
Get alerted when new PERITONEAL CANCER trials appear
Sign up with your email to follow new studies for PERITONEAL CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail aims to stall ovarian cancer recurrence
Disease control OngoingThis Phase 3 trial is testing whether adding mirvetuximab soravtansine (a drug that targets a protein called FRα on cancer cells) to standard bevacizumab maintenance therapy can delay cancer progression in women with recurrent ovarian, fallopian tube, or peritoneal cancer. The st…
Matched conditions: PERITONEAL CANCER
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug duo aims to stall ovarian Cancer's return
Disease control OngoingThis phase 2 trial is testing whether adding oregovomab (an antibody) to niraparib (a daily pill) can better control platinum-sensitive recurrent ovarian cancer. Ten women whose cancer came back after initial chemotherapy will receive both drugs for 12 weeks. The main goal is to …
Matched conditions: PERITONEAL CANCER
Phase: PHASE2 • Sponsor: CanariaBio Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New drug cocktail shows promise for recurrent ovarian cancer
Disease control OngoingThis study tested a combination of three drugs—nivolumab, bevacizumab, and rucaparib—in 72 people whose ovarian, fallopian tube, or peritoneal cancer had returned after standard treatment. The goal was to see if the drugs could shrink tumors or slow the cancer's growth. While som…
Matched conditions: PERITONEAL CANCER
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Ovarian cancer hope: new antibody combo aims to delay disease worsening
Disease control OngoingThis Phase 3 trial tests whether adding an experimental antibody called oregovomab to standard chemotherapy (paclitaxel and carboplatin) helps people with newly diagnosed advanced ovarian cancer live longer without their cancer getting worse. About 615 participants who had surger…
Matched conditions: PERITONEAL CANCER
Phase: PHASE3 • Sponsor: CanariaBio Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Could chemo around surgery beat cancer spread in the belly?
Disease control OngoingThis study tests whether giving chemotherapy before and after surgery (plus heated chemo directly into the abdomen) helps people with colorectal cancer that has spread to the lining of the abdomen live longer. About 358 adults with resectable disease are randomly assigned to eith…
Matched conditions: PERITONEAL CANCER
Phase: PHASE2, PHASE3 • Sponsor: Koen Rovers • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Experimental CAR T-Cell therapy targets Hard-to-Treat ovarian cancer
Disease control OngoingThis early-phase study tests a new treatment for women with recurrent epithelial ovarian cancer. The therapy uses the patient's own immune cells, modified to find and attack cancer cells that carry a protein called B7-H3. The main goal is to check safety and find the best dose, w…
Matched conditions: PERITONEAL CANCER
Phase: PHASE1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New drug BL-M17D1 targets Hard-to-Treat HER2 cancers in early trial
Disease control OngoingThis early-stage study tests a new drug called BL-M17D1 in 120 adults with advanced solid tumors that have HER2 protein or gene changes. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Participants must have tried at least one standard…
Matched conditions: PERITONEAL CANCER
Phase: PHASE1 • Sponsor: SystImmune Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Phone therapy shows promise for depression in ovarian cancer patients
Symptom relief OngoingThis study looks at whether weekly phone counseling can help identify and treat depression in women with ovarian, peritoneal, or fallopian tube cancer. About 409 participants will either receive phone counseling or standard care with resource lists. The goal is to see which appro…
Matched conditions: PERITONEAL CANCER
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
Can acupuncture with electricity help cancer patients recover from aggressive treatment?
Symptom relief OngoingThis study looks at whether electroacupuncture (a type of acupuncture with mild electrical pulses) can help manage pain, nausea, diarrhea, and insomnia in people who have had cytoreductive surgery and heated chemotherapy for cancer. The trial will enroll 20 patients to see if the…
Matched conditions: PERITONEAL CANCER
Phase: NA • Sponsor: University of California, Irvine • Aim: Symptom relief
Last updated Jun 27, 2026 09:05 UTC
-
What makes ovarian cancer survivors thrive? scientists investigate diet, mood, and support
Knowledge-focused OngoingThis study looks at women who have lived at least seven years after an ovarian cancer diagnosis. Researchers want to learn how diet, exercise, emotions, and social support may be linked to long-term survival. Participants fill out questionnaires and take part in interviews about …
Matched conditions: PERITONEAL CANCER
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
New study aims to ease life after ovarian and endometrial cancer
Knowledge-focused OngoingThis study tests a personalized post-cancer care plan for women who have finished treatment for ovarian or endometrial cancer. About 99 participants will receive a day of support care and a tailored plan to address their needs. The goal is to see if this approach improves their l…
Matched conditions: PERITONEAL CANCER
Phase: NA • Sponsor: Centre Francois Baclesse • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
Can a simple nudge get ovarian cancer patients to the right specialist faster?
Knowledge-focused OngoingThis study tests whether a gentle reminder to doctors can increase referrals to gynecologic oncology for women with suspicious ovarian masses. Researchers will send a message to ordering providers within 48 hours of imaging results, encouraging them to refer patients. The study i…
Matched conditions: PERITONEAL CANCER
Phase: NA • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Knowledge-focused
Last updated Jun 26, 2026 19:04 UTC